Tune Therapeutics
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Morris St Ste 320, Durham, North Car...Website
www.tunetx.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Tune Therapeutics
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine. The company is based in Durham, North Carolina.Explore more
Tune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Tune Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Tune Therapeutics
Funding: Get notified immidiatlly once Tune Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tune Therapeutics recently announced quarterly report
Check if Tune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Tune Therapeutics had a recent Job posting/layoffs
Check out if Tune Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Tune Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Tune Therapeutics
Compare insights from companies similar to Tune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tune Therapeutics
$16.9M
51-200
Private
$175M
2020
AM
Akira MatsunoCo-Founder & President & Chief Operating Officer & Chief Financial Officer
Company Profile Activity
Activity Insights
Tune Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tune Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tune Therapeutics.
Tune Therapeutics financials insights
Gather financial insights about Tune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$175M
Tune Therapeutics Tech Stack
A closer look at the technologies used by Tune Therapeutics
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
Funding
Funding
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Tune Therapeutics News & Media
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, MD will be its new CEO and Chairman of the Board. “I am honored and excited to be taking on this new role with Tune, and to be leading such a talented team,” said Dr. McHutchison. “The company has such a strong scientific foundation, and the modality has enormous potential to address a vast rangeDuke professor-led biotech company raises $175 million to advance epigenome editing ...
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic Hepatitis B — a viral infection that damages the liver and affects millions globally.Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. “It is deeply gratifying to have seen this platform and company evolve so far,” said Tune Co-Founder Dr. Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform. “Tune has already achieved a global laTune Therapeutics Receives Approval to Initiate Clinical Trial in Hong Kong for HepB Epigenetic Silencer
DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong after receiving a Certificate for Clinical Trial from the Hong Kong Department of Health. This marks the second global approval to commence a Phase 1b clinical trial for Tune-401, an investigational epigenetic silencing therapy designed to treat chronic hepatitis B (CHB). “We’re taking a fresh angle on the battle against chronic hepatitis
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tune Therapeutics
Sign Up For FreeTo access detailed company insights
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine. The company is based in Durham, North Carolina.... Read More
